Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate whether Dabigatran itself reduces ADP induced platelet aggregation measured by MEA as compared to Phenprocoumon after a two-week treatment with either agent.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Deutsches Herzzentrum Muenchen
• Treatments: Dabigatran; Phenprocoumon

Criteria

Key Inclusion Criteria:

• Patients with atrial fibrillation and an indication for oral anticoagulation (CHA2DS2-VASc score≥ 1).

• Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.

Key Exclusion Criteria:

• Age ≤18 years

• Cardiogenic shock

• Current therapy with dabigatran

• Current, recent (2 weeks) or expected (1 week) clopidogrel therapy

• Contraindication for oral anticoagulation

• Active bleeding

• Known allergy or intolerance to the study medications: dabigatran, phenprocoumon